Informational only — Not medical advice. Always consult a licensed healthcare provider.

MedBD
বাং
Community data Updated 2 months ago
🌐 বাংলায় দেখুন

Indications

Epilepsy

Leptal is indicated for the following uses. In adults, it is used as monotherapy or adjunctive therapy in the treatment of partial seizures. In children, it is used as monotherapy in the treatment of partial seizures in those aged 4 to 16 years, and as adjunctive therapy in the treatment of partial seizures in those aged 2 to 16 years.

⚠️ Always consult a registered physician before taking any medicine.

Pharmacology

Oxcarbazepine's effect on seizures comes mainly from its 10-monohydroxy metabolite, known as MHD. It is not fully understood how Oxcarbazepine and MHD prevent seizures, but laboratory studies of nerve cell electrical activity show that they block voltage-sensitive sodium channels. This calms overexcited nerve membranes, slows repeated firing of neurons, and reduces the spread of signals between nerve cells. These actions are believed to play a key role in stopping seizures from spreading through the brain. The drug's anticonvulsant effect may also be helped by an increase in potassium conductance and by changes in the activity of high voltage activated calcium channels. Oxcarbazepine and MHD have not been shown to interact in any meaningful way with the brain's neurotransmitter or receptor sites.

Pregnancy & Breastfeeding

Pregnancy Category C. Well-controlled clinical studies in pregnant women are lacking, so Oxcarbazepine should only be used during pregnancy if the potential benefit to the mother outweighs the potential risk to the fetus. Oxcarbazepine also passes into breast milk, with a milk-to-plasma concentration ratio of 0.5, and for this reason it should not be used while breastfeeding.

⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.

Dosage Reference

⚠️ Reference ranges from official sources only. Consult your doctor for personalized dosing.

Adults: Adults: treatment is started at 600 mg a day, given in two divided doses. Adjunctive therapy: the dose may be raised by no more than 600 mg a day at roughly weekly intervals, to a recommended daily dose of 1200 mg a day. Conversion to monotherapy: the concomitant antiepileptic drug is withdrawn over 3 to 6 weeks, while the maximum dose of oxcarbazepine is reached within 2 to 4 weeks by increments of 600 mg a day at weekly intervals, up to a recommended daily dose of 2400 mg a day. Initiation of monotherapy: the dose is increased by 300 mg a day every third day, up to 1200 mg a day. For patients with a creatinine clearance below 30 mL/min, treatment is started at half the usual starting dose and increased slowly. Pediatrics: treatment is started at 8 to 10 mg/kg a day, given in two divided doses. For patients aged 2 to under 4 years and weighing under 20 kg, a starting dose of 16 to 20 mg/kg a day may be considered. The recommended daily dose depends on the patient's weight. Adjunctive patients aged 2 to 16 years: for patients aged 4 to 16 years, the target maintenance dose should be reached over 2 weeks; for patients aged 2 to under 4 years, the maximum maintenance dose should be reached over 2 to 4 weeks and should not exceed 60 mg/kg a day. Conversion to monotherapy for patients aged 4 to 16 years: the dose may be raised by no more than 10 mg/kg a day at weekly intervals, and the concomitant antiepileptic drugs can be fully withdrawn over 3 to 6 weeks. Initiation of monotherapy for patients aged 4 to 16 years: the dose is increased by 5 mg/kg a day every third day.

Side Effects & Interactions

Side Effects

No side-effect data recorded yet.